2015 Exits: Biotech’s Big Year
This article was originally published in Start Up
Fewer companies went public in 2015 than during the peak year of 2014, but on average 2015’s US IPO crop raised more money and at better valuations. And thanks to a jump in private biotech acquisition volume and valuations, investors enjoyed a tremendous year for biotech exits.
You may also be interested in...
Latest data suggest startup Axovant has a plausible path for its modestly effective RVT-101 toward approval, but the field is still inherently risky and the market is wary nevertheless.
Since 2013, investors have rallied around biotech IPOs like never before. START-UP looks at the current window and the implications of investor enthusiasm for newly public companies.
In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.